280 related articles for article (PubMed ID: 8234866)
21. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
22. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
24. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
25. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
26. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
27. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
Gerard SK; Dam HQ
Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
[No Abstract] [Full Text] [Related]
28. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
[TBL] [Abstract][Full Text] [Related]
29. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
30. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
Díez JJ; Grande E; Iglesias P
Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma.
Lips P; Comans EF; Hoekstra OS; van der Poest Clement E; van Mourik JC; Teule GJ
Neth J Med; 2000 Oct; 57(4):150-6. PubMed ID: 11006491
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography.
Jadvar H; McDougall IR; Segall GM
Nucl Med Commun; 1998 Jun; 19(6):547-54. PubMed ID: 10234658
[TBL] [Abstract][Full Text] [Related]
33. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Chao TC
Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
[TBL] [Abstract][Full Text] [Related]
34. Differentiated thyroid cancer presenting with thyrotoxicosis due to functioning metastases.
Haq M; Hyer S; Flux G; Cook G; Harmer C
Br J Radiol; 2007 Feb; 80(950):e38-43. PubMed ID: 17495053
[TBL] [Abstract][Full Text] [Related]
35. [Differentiated thyroid gland carcinoma in a scintigraphically hot thyroid nodule: diagnosis and interdisciplinary therapeutic management].
Stahl A; Hess U; Harms J; Zwicknagl M; Langhammer H
Wien Klin Wochenschr; 2002 Jun; 114(10-11):410-4. PubMed ID: 12708097
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
37. Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake.
Oyen WJ; Mudde AH; van den Broek WJ; Corstens FH
J Nucl Med; 1995 Apr; 36(4):613-5. PubMed ID: 7699452
[TBL] [Abstract][Full Text] [Related]
38. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
Samuel AM; Rajashekharrao B
J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
[TBL] [Abstract][Full Text] [Related]
39. [Outcomes of long-term combined treatment in follicular thyroid carcinoma].
Baranauskas Z; Valuckas KP; Tiskevicius S
Medicina (Kaunas); 2010; 46(4):268-74. PubMed ID: 20571295
[TBL] [Abstract][Full Text] [Related]
40. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer.
Maxon HR
Q J Nucl Med; 1999 Dec; 43(4):313-23. PubMed ID: 10731782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
